+ Reply to Thread
Page 1 of 2 1 2 LastLast
Results 1 to 10 of 12
  1. #1
    Member
    Join Date
    Jul 2013
    Posts
    42

    Default Crowdfund 2014 AA treatment pipeline report

    Hello,

    I think we should club together $2000 and get this report - http://www.aboutpharma.com/blog/2014...search-report/

    It provides info on all of the treatments in the works, some I've never heard of before along with info on their state of development and mechanisms of action, I reckon it could give everyone a good overview of the state of affairs where we're at etc. before the conference in Nov and perhaps spur further research etc.

    I'd happily chip in $20, preferably a trusted/reputable forum member could coordinate the sourcing of funds and purchasing/uploading of report.

  2. #2
    Senior Member
    Join Date
    Jul 2011
    Location
    agaexperts.meteor.com
    Posts
    1,405

    Default

    Quote Originally Posted by sosa56 View Post
    Hello,

    I think we should club together $2000 and get this report - http://www.aboutpharma.com/blog/2014...search-report/

    It provides info on all of the treatments in the works, some I've never heard of before along with info on their state of development and mechanisms of action, I reckon it could give everyone a good overview of the state of affairs where we're at etc. before the conference in Nov and perhaps spur further research etc.

    I'd happily chip in $20, preferably a trusted/reputable forum member could coordinate the sourcing of funds and purchasing/uploading of report.
    Probably not much extra info in there.... just google the companies you haven't heard of

  3. #3
    Senior Member
    Join Date
    Jul 2011
    Location
    agaexperts.meteor.com
    Posts
    1,405

    Default

    Drugs profile discussed in this Pompe disease Pipeline Review H2 2014 report include

    bimatoprost, meh.


    CB-0301, meh.


    finasteride, ....


    Hair Stimulating Complex, meh.



    RCH-01, replicel



    Refagro,

    http://www.reportlinker.com/p0166736...ne-Review.html


    RES-440,

    RES-440, an ester of a carboxylic acid derivative of hydroxyflutamide, is a synthetic, non-steroidal compound and represents one of four structural classes of topical anti-androgenic compounds in the RestorGenex portfolio. Management believes RES-440 is the first topical anti-androgen engineered for rapid deactivation by hydrolytic enzymes near the site of application to a single inactive metabolite, thus, sparing internal androgen sensitive tissues. Our data demonstrate that RES-440 is a very potent anti-androgen. RES-441, the expected major metabolite of RES-440 has no detectable anti-androgenic activity. To date, no other topical anti-androgen has been developed and marketed successfully. We believe the root cause of this failure has been due to the systemic safety issues that arise with locally effective doses.

    RES-440 is currently under development for the treatment of acne.

    Excess androgenic hormones (testosterone and 5-dihydrotestosterone) in the skin are the root cause of acne, seborrhea, alopecia and hirsutism. Excess skin androgens lead to the overproduction of sebum which can block skin pores and lead to acne through localized infection and inflammation. A topical anti-androgen may block the actions of androgenic hormones in the skin and heal acne. In some women, excess skin androgens can lead to unwanted localized hair growth (hirsutism). A topical anti-androgen applied to those skin areas may greatly minimize excess body hair growth caused by excess androgens in the skin. Paradoxically, excess androgen in the scalp can cause androgenic alopecia or baldness and is the most common cause of hair loss affecting both men and women. An anti-androgen applied to the scalp at the first signs of thinning may block the actions of androgenic hormones.


    RK-023,

    In January 2011, the company announced that the Phase 2a clinical study of RK-023 to treat androgenetic alopecia has been completed. The double-blind, placebo-controlled study assessed the safety and preliminary efficacy of RK-023 when applied to the scalp for 13 weeks (2 mL to a hair-thinning part of scalp twice daily). Forty-eight patients (24 cases of the RK-023 group and 24 cases of the placebo group) were enrolled in this study. There was no severe adverse event. The frequency of mild adverse events was equal in both groups. In pharmacokinetic study, the main metabolite of RK-023 was slightly detected in plasma of only one patient. This showed that the transdermal absorption of RK-023 from the scalp was low. In the efficacy assessment, the RK-023 group showed possibility of improvement in global photo assessment and in numbers of anagen hair from the baseline compared with the placebo group.


    SM-04554, meh. Doubt more info here then we know.


    Small Molecule for Androgenic Alopecia, vague



    pay me $2,000 now

  4. #4
    Senior Member
    Join Date
    Jul 2011
    Location
    agaexperts.meteor.com
    Posts
    1,405

    Default

    ntents: List of Tables
    List of Figures
    Introduction
    REPORT COVERAGE
    Androgenic Alopecia Overview
    Therapeutics Development
    Pipeline Products for Androgenic Alopecia - Overview
    Pipeline Products for Androgenic Alopecia - Comparative Analysis
    Androgenic Alopecia - Therapeutics under Development by Companies
    Androgenic Alopecia - Pipeline Products Glance
    Clinical Stage Products
    Early Stage Products
    Androgenic Alopecia - Products under Development by Companies
    Androgenic Alopecia - Companies Involved in Therapeutics Development
    Allergan, Inc.
    Dong-A Socio Group
    Histogen, Inc.
    Kasiak Research Pvt. Ltd.
    Molplex Ltd.
    Polichem S.A.
    R-Tech Ueno, Ltd.
    RepliCel Life Sciences, Inc.
    RestorGenex Corporation
    SWITCH Biotech LLC
    Valeant Pharmaceuticals International, Inc.
    Androgenic Alopecia - Therapeutics Assessment
    Assessment by Monotherapy Products
    Assessment by Combination Products
    Assessment by Target
    Assessment by Mechanism of Action
    Assessment by Route of Administration
    Assessment by Molecule Type
    Drug Profiles
    (finasteride + minoxidil) - Drug Profile
    Product Description
    Mechanism of Action
    R&D Progress
    bimatoprost - Drug Profile
    Product Description
    Mechanism of Action
    R&D Progress
    CB-0301 - Drug Profile
    Product Description
    Mechanism of Action
    R&D Progress
    finasteride - Drug Profile
    Product Description
    Mechanism of Action
    R&D Progress
    Hair Stimulating Complex (HSC) - Drug Profile
    Product Description
    Mechanism of Action
    R&D Progress
    RCH-01 - Drug Profile
    Product Description
    Mechanism of Action
    R&D Progress
    Refagro - Drug Profile
    Product Description
    Mechanism of Action
    R&D Progress
    RES-440 - Drug Profile
    Product Description
    Mechanism of Action
    R&D Progress
    RK-023 - Drug Profile
    Product Description
    Mechanism of Action
    R&D Progress
    SM-04554 - Drug Profile
    Product Description
    Mechanism of Action
    R&D Progress
    Small Molecule for Androgenic Alopecia - Drug Profile
    Product Description
    Mechanism of Action
    R&D Progress
    Small Molecules for Androgenic Alopecia - Drug Profile
    Product Description
    Mechanism of Action
    R&D Progress
    Androgenic Alopecia - Recent Pipeline Updates
    Androgenic Alopecia - Dormant Projects
    Appendix
    Methodology
    Coverage
    Secondary Research
    Primary Research
    Expert Panel Validation
    Contact Us
    Disclaimer
    List of Tables
    Number of Products under Development for Androgenic Alopecia, H2 2014
    Number of Products under Development for Androgenic Alopecia - Comparative Analysis, H2 2014
    Number of Products under Development by Companies, H2 2014
    Comparative Analysis by Clinical Stage Development, H2 2014
    Comparative Analysis by Early Stage Development, H2 2014
    Products under Development by Companies, H2 2014
    Androgenic Alopecia - Pipeline by Allergan, Inc., H2 2014
    Androgenic Alopecia - Pipeline by Dong-A Socio Group, H2 2014
    Androgenic Alopecia - Pipeline by Histogen, Inc., H2 2014
    Androgenic Alopecia - Pipeline by Kasiak Research Pvt. Ltd., H2 2014
    Androgenic Alopecia - Pipeline by Molplex Ltd., H2 2014
    Androgenic Alopecia - Pipeline by Polichem S.A., H2 2014
    Androgenic Alopecia - Pipeline by R-Tech Ueno, Ltd., H2 2014
    Androgenic Alopecia - Pipeline by RepliCel Life Sciences, Inc., H2 2014
    Androgenic Alopecia - Pipeline by RestorGenex Corporation, H2 2014
    Androgenic Alopecia - Pipeline by SWITCH Biotech LLC, H2 2014
    Androgenic Alopecia - Pipeline by Valeant Pharmaceuticals International, Inc., H2 2014
    Assessment by Monotherapy Products, H2 2014
    Assessment by Combination Products, H2 2014
    Number of Products by Stage and Target, H2 2014
    Number of Products by Stage and Mechanism of Action, H2 2014
    Number of Products by Stage and Route of Administration, H2 2014
    Number of Products by Stage and Molecule Type, H2 2014
    Androgenic Alopecia Therapeutics - Recent Pipeline Updates, H2 2014
    Androgenic Alopecia - Dormant Projects, H2 2014
    List of Figures
    Number of Products under Development for Androgenic Alopecia, H2 2014
    Number of Products under Development for Androgenic Alopecia - Comparative Analysis, H2 2014
    Number of Products under Development by Companies, H2 2014
    Comparative Analysis by Clinical Stage Development, H2 2014
    Comparative Analysis by Early Stage Products, H2 2014
    Assessment by Monotherapy Products, H2 2014
    Number of Products by Top 10 Targets, H2 2014
    Number of Products by Stage and Top 10 Targets, H2 2014
    Number of Products by Top 10 Mechanism of Actions, H2 2014
    Number of Products by Stage and Top 10 Mechanism of Actions, H2 2014
    Number of Products by Top 10 Routes of Administration, H2 2014
    Number of Products by Stage and Top 10 Routes of Administration, H2 2014
    Number of Products by Top 10 Molecule Types, H2 2014
    Number of Products by Stage and Top 10 Molecule Types, H2 2014

  5. #5
    Senior Member
    Join Date
    Apr 2015
    Posts
    413

    Default

    Is there not one for 2015?

  6. #6
    Member
    Join Date
    Jul 2013
    Posts
    42

    Default

    Seems this is the latest one, but hardly much is likely to have changed in 8 months

  7. #7
    Senior Member
    Join Date
    May 2014
    Posts
    561

    Default

    wasn't aware that such a report exists.
    i think it's a good idea to buy it. i would even say, we have to buy the 2015 version as well, if it gets released by the end of the year, then we can compare changes.
    if nobody is interested to see the progress/changes, then it probably makes sense to wait for the 2015 version.

    but i see a problem here: we're not allowed to buy it and then put it online for everyone, are we? we need to workaround this somehow.

  8. #8
    Member
    Join Date
    Jul 2013
    Posts
    42

    Default

    Sheeet if each of the people that have viewed this thread put in like $5 we'd be able to buy the report, obviously like when you buy a film or music track you're not allowed to distribute it, but one someone has paid for a piece of IP it's up to them what they do with it right? Someone could always buy the report and then pass it onto a friend and that friend could upload the report onto a file hoster like mega.nz and then post the link here from an anon account, it's not as if the report publisher would get $2000 out of readers on this forum any other way right?

  9. #9
    Member
    Join Date
    Jul 2013
    Posts
    42

    Default

    So noone up on this? This forum makes me laugh honestly, always see threads where guys are discussing buying grey market chems from China that haven't finished clinical trials to slap them on their heads lol but won't put in for a comprehensive report that could go a long way to answering all of our questions on the state of the market leading up to the conference in Nov. smh

  10. #10
    Member
    Join Date
    Aug 2015
    Posts
    31

    Default

    Okey so we need a trusted veteran on this forum which can make things happend. I am willing to pay 5 bucks!

    It seems we have like 4-5 who are willing to pay. How many more can we get?

Similar Threads

  1. Crowdfund report
    By sosa56 in forum Cutting Edge / Future Treatments
    Replies: 1
    Last Post: 09-06-2015, 06:26 AM
  2. Crowdfund a position in Tsuji Labs?
    By NeedHairASAP in forum Cutting Edge / Future Treatments
    Replies: 17
    Last Post: 10-04-2013, 03:07 PM
  3. Crowdfund Salaries
    By NeedHairASAP in forum Cutting Edge / Future Treatments
    Replies: 40
    Last Post: 09-07-2013, 07:54 AM
  4. Clinical Pipeline Products
    By UK Boy in forum Cutting Edge / Future Treatments
    Replies: 14
    Last Post: 07-26-2013, 10:12 AM
  5. REPLICEL posts pipeline timeframe
    By comeonreplicel in forum Cutting Edge / Future Treatments
    Replies: 35
    Last Post: 05-23-2013, 01:38 PM

Posting Permissions

  • You may not post new threads
  • You may not post replies
  • You may not post attachments
  • You may not edit your posts

» IAHRS

hair transplant surgeons

» The Bald Truth